Clinical Trials Browser

INDUSTRY × Alpelisib × Clear all

Breast Neoplasms

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Advanced Breast Cancer

Breast Neoplasms

Multiple Endocrine Neoplasia Type 1

Triple Negative Breast Neoplasms

Advanced HER2+Breast Cancer

Breast Neoplasms

Breast Neoplasms

HER2-positive Metastatic Breast Cancer

Ovarian Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Endometrial Neoplasms

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Advanced Breast Cancer

Hereditary Sensory and Autonomic Neuropathies

Advanced or Metastatic ER+ Breast Cancer

Breast Neoplasms

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Hereditary Sensory and Autonomic Neuropathies

3rd Line GIST

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Breast Neoplasms

Multiple Myeloma, Recurrence

Adenocarcinoma of Lung

Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Acrocephalosyndactylia, Breast Neoplasms

Advanced Solid Tumor

Breast Neoplasms, Head and Neck Neoplasms, Neoplasms

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Advanced Solid Tumors With an Alteration of the PIK3CA Gene

Pre-menopausal Breast Cancer

Breast Neoplasms

Breast Neoplasms, Ovarian Neoplasms

Advanced and Selected Solid Tumors

Clinical Trials

Managed Access Programs for BYL719, Alpelisib

EPIK-L1

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

EPIK-B5

ALPINIST

EPIK-B3

EPIK-B2

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

SPEAR

VIKTORIA-1

INAVO121

BYLieve

ELEVATE

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

AMEERA-1

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

A Post Marketing Surveillance on Piqray in Korea

EMBER

SOLAR-1

EPIK-B4

BioItaLEE

TELEPIK

EPIK-P1

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

B-YOND

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors